- Home
- H vs ITCI Comparison
H vs ITCI Comparison
Compare H & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- H
- ITCI
- Stock Information
- Founded
- H 1957
- ITCI 2002
- Country
- H United States
- ITCI United States
- Employees
- H N/A
- ITCI N/A
- Industry
- H Hotels/Resorts
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- H Consumer Discretionary
- ITCI Health Care
- Exchange
- H Nasdaq
- ITCI Nasdaq
- Market Cap
- H 15.1B
- ITCI 13.5B
- IPO Year
- H 2009
- ITCI N/A
- Fundamental
- Price
- H $140.11
- ITCI $128.60
- Analyst Decision
- H Buy
- ITCI Buy
- Analyst Count
- H 17
- ITCI 13
- Target Price
- H $162.85
- ITCI $103.92
- AVG Volume (30 Days)
- H 835.0K
- ITCI 2.2M
- Earning Date
- H 02-13-2025
- ITCI 02-21-2025
- Dividend Yield
- H 0.43%
- ITCI N/A
- EPS Growth
- H 517.07
- ITCI N/A
- EPS
- H 12.65
- ITCI N/A
- Revenue
- H $3,296,000,000.00
- ITCI $613,728,000.00
- Revenue This Year
- H $117.48
- ITCI $48.28
- Revenue Next Year
- H $5.97
- ITCI $37.34
- P/E Ratio
- H $11.05
- ITCI N/A
- Revenue Growth
- H N/A
- ITCI 46.08
- 52 Week Low
- H $128.91
- ITCI $63.30
- 52 Week High
- H $168.20
- ITCI $128.77
- Technical
- Relative Strength Index (RSI)
- H 32.55
- ITCI 83.90
- Support Level
- H $141.52
- ITCI $126.88
- Resistance Level
- H $147.52
- ITCI $128.19
- Average True Range (ATR)
- H 5.52
- ITCI 0.41
- MACD
- H -2.01
- ITCI -1.30
- Stochastic Oscillator
- H 2.01
- ITCI 91.01
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (4% of total rooms) and managed and franchised (96%) properties across around 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 54% Americas, 22% rest of world, and 23% Asia-Pacific.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.